in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharmaceuticals: DSM Joint Venture Percivia Ceases Inhouse Activities
3:06 AM MDT | April 26, 2012 | Alex Scott
DSM and Crucell (Leiden, the Netherlands), a biotech firm, have pulled the plug on all inhouse projects at their biosimilar drugs joint venture company Percivia (Cambridge, MA). Set up in 2007, “Percivia will remain as an entity to serve existing licensees,” DSM tells CW. DSM says that an undisclosed number of staff will be made redundant as a result of the jv’s change of strategy. Percivia’s business has been based on the use of Crucell’s PER.C6 engineered human cell line that has been specifically developed for industrial...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee